Wearable device-telemonitored Baduanjin for chronic heart failure: A systematic review of effects on exercise tolerance and cardiac function.
Xin Liu, Xiaona He, Yuyue Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed the impact of wearable device-telemonitored Baduanjin on exercise tolerance and cardiac function in patients with chronic heart failure (CHF). Three randomized controlled trials with 248 participants indicated significant improvements, including a 6-minute walking distance of 568.58 m compared to 367.47 m (P < 0.05) and peak oxygen uptake of 19.00 ml/[kg·min] versus 17.00 ml/[kg·min] (P < 0.001).
Key findings
- 6-minute walking distance improved to 568.58 m vs. 367.47 m (P < 0.05).
- Peak oxygen uptake increased to 19.00 ml/[kg·min] vs. 17.00 ml/[kg·min] (P < 0.001).
- Left ventricular ejection fraction improved to 52.60% vs. 45.28% and 42.79% (P < 0.05).
- No exercise-related adverse events were reported.
Why it matters
The findings suggest that integrating wearable technology with Baduanjin may enhance exercise capacity and cardiac function in CHF patients, potentially leading to better management of the condition and improved patient outcomes.
What to keep in mind
The review's conclusions are based on a narrative synthesis due to significant clinical heterogeneity among the included studies.